The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
WHERE ARE THESE RESULTS?
18th November 2020, RNS:
"Today, the Company provides an update on the recently published[1] in-vitro results from a separate, independent laboratory study undertaken at Cardiff University by Dr Richard Stanton and his colleagues.
In their published in-vitro[2] study, scientists at Cardiff University concluded that Venture Life's two CPC based mouthwashes eradicated the SARS-CoV-2 (COVID-19) virus completely (>5log reduction, equivalent to 99.999%) within a 30 second exposure."
1st December 2021, RNS:
"The Company continues to await the publication of the peer-reviewed in vivo study carried out by Cardiff University, which was completed in April this year. Whilst the Board is disappointed that this has taken longer than expected to publish, and does acknowledge that the timing is outside the control of Cardiff University, it is hopeful the final publication will be available soon. Further, the Company notes the recent announcement made by Salisbury Hospital regarding specific mouth care guidance for patients with Covid-19. As well as regular toothbrushing, the guidance also suggests that both Dentyl Dual Action and Dentyl Fresh Protect should be used. The Company understands this guidance was based on research conducted by Doctors at Salisbury Hospital, as well as the in-vitro (lab based) results widely published by Cardiff University in November 2020."
How is my throat going to be a fundamentally different environment from a test tube at the same temperature?
Open Orphan have been conducting trials where they infect volunteers with the virus deliberately: that way they can study the progress of the disease from day 1. According to one of the BBC science programmes (Inside Science?) that shows it starts in the throat, moves to the nose, then on. Gargling 1/2 X per day with something that kills 99.999% of the virus should therefore eliminate it or slow it down so much the body has no problem preparing for it and dealing with it. Thus effectively it would work as a free vaccine as well. It's CHEAP, it's EASY, it's already known as SAFE, it's already IN PRODUCTION, with DISTRIBUTION CHANNELS IN PLACE WORLDWIDE.
I emailed - politely - but got no answer.
I cannot see how this would not have saved many, many lives. The trial finished in APRIL.
Sometimes it's right to be very, very angry.
I work with brokers for part of my stuff. Rang them to get into the placing within 5 minutes of the RNS yesterday - and they still didn't manage it. But I didn't know till it was too late this morning.
Frustrating. So now I own a smaller proportion of a slightly larger company, into which others have been allowed to buy at a 25% discount. AndI did everything right....
BUT it's a good sign of things to come. Still v v positive about where this is going.
APART from the rare earths this is how the CEO began last week:
"The results of the programme have demonstrated that the gold system at Clarke is considerable in size, open to the north and continues to present as a compelling target to add further ounces to the existing Mineral Resource Estimate."
Then the rare earths add a whole new dimension. Even if the gold hadn't been economic to mine in the end [no hint of that that I've seen] with the REE it then probably would have been. And the SP was right at the bottom. I don't get the problem.
Agreed: opportunity. Why be a holder if you don't think it has prospects?
Sadly I've v little money free to take advantage - and by tomorrow morning it's probably done?? I don't know how these things work.
This from 8th Feb:
"Whilst the Board believes that the price of 40 pence per share significantly undervalues the Company discussions between the parties remain ongoing and, in accordance with Rule 2.6(c) of the Code, the Company has requested, and the Panel on Takeovers and Mergers (the "Takeover Panel") has consented to, an extension to the deadline by which Kofax is required either to announce a firm intention to make an offer for Tungsten in accordance with Rule 2.7 of the Code or to announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. Such announcement must now be made by not later than 5.00pm on 22 February 2022. This deadline can be extended by the Board of Tungsten, with the consent of the Takeover Panel.
There can be no certainty that a firm offer will be made nor as to the terms of any such offer. A further announcement will be made in due course."
According to this the next deadline is a week today. Does anyone know further?
Still frustrated. I lost money here before, now it seems to have got its act together and have real prospects.
For example this news from the company website that they didn't seem to think was worth an RNS (!!):
"London, 5 January 2022: Tungsten Corporation plc, a leading provider of digital financial management and software solutions is collaborating with Amazon Business to deliver global e-invoicing in Europe and the U.S.A.
Amazon Business is an online store and procurement solution that helps millions of customers worldwide—from small businesses, schools, hospitals, non-profit organisations, and government agencies, to large enterprises with global operations—reshape their procurement with cost and time savings, greater productivity, and insightful purchasing analytics. This integration will allow Amazon Business customers to automate invoice processing via the Tungsten e-invoicing network."
Now up to 12.31%.
Keen.
"I hope to add here at these levels. Just waiting for news elsewhere to sell into then will be topping up.I hope to add here at these levels. Just waiting for news elsewhere to sell into then will be topping up."
Me too, Trek. SNG?????? :)
I note also it's produced by fungi through fermentation of carbohydrates, such as glucose or molasses. If they could use other less sugary carbohydrates/hydrocarbons such as wood pulp, sewage etc it would be such an amazing positive circle. Who knows, might be able to produce hydrogen! Dream on Qd.... [I'm no chemist!]
What a great time to have bought back in. Yes, it's jam tomorrow, but it is a shipload of jam if it comes! And it's the 2nd load in just 6 days, 3rd in 7 weeks. Meanwhile as I'm sure you've noticed it continues to progress in the areas where it already has a foothold - and the SP has plummeted on what looks like just sentiment.
Topped up, even though it's painful when it's risen 20%.
Agreed, and more than.
If some unknown pure exploration outfit had discovered these clays on their site their SP would go stratospheric. A pure play. But because this is on an existing gold prospect it's so easy to see it like just some good drill results, beefing up the known resource. Yes, a 10% improvement.....
No it's not. It seems to me they're saying it's the equivalent of a whole new prospect.
Even better than a whole new prospect. The further drilling goes in with the gold drilling. The finance goes in with the gold finance. The infrastructure goes in with the gold infrastructure - which makes it GREEN.... (And did you see there's great links nearby?). Even the skilled people don't have to double up. Plus it's exactly what the western world needs at the moment with the geopolitics as they are.
All IMHO. Very, very amateur! I put too much in here before, timed it badly, am still nearly 40% down.... so am I going to put my money where my mouth is and buy even more???
Needs some news, but it looks like it's levelled out in the absence.
Thanks for the info and updates, Rivaldo.
(Sharecast News) - Analysts at Berenberg initiated coverage on software firm Bango on Friday with a 300.0p target price and 'buy' rating, stating the stock offered "bang for your buck".
Berenberg said Bango, an alternative payments and purchase behaviour targeting platform, more often than not gets viewed as a subscale direct carrier billing business when compared to its UK-listed peer, Boku.
However, the analysts stated that while Bango is smaller by market share, it differentiates itself through its subscription bundling service offered to network carriers and the ability for both physical and digital goods to be transacted through its platform.
The German bank said with its payment data now being used to fuel a new advertising tool for mobile app developers, which was gaining rapid adoption, Bango has broadened its offering and enlarged its revenue opportunity.
"We expect the company to continue compounding sales at a 30% compound annual growth rate, but for earnings growth to outpace this significantly, as recent investment in its platform pays off," said Berenberg. "Bango trades on 13x 2023 EV/EBITDA, a circa 30% discount to Boku and other global payment peers."
(Sharecast News) - Intellectual property-focussed investor Tekcapital updated the market on its portfolio company Guident on Friday, reporting that it had now filed its eighth patent application.
The AIM-traded firm said Guident, which develops software for improving the safety of autonomous vehicles (AVs) and delivery robots, had filed the patent application for improvements to its remote monitoring and control centre for AVs.
It said the United States patent application was titled 'Near Real-Time Data and Video Streaming System for a Vehicle, Robot or Drone'.
Tekcapital also said that Guident attended the 2022 Consumer Electronic Show (CES) in Las Vegas, and while there, it held meetings with potential customers and partners.
It said Guident reported positive feedback and a desire from potential partners to collaborate, with discussions said to be ongoing.
Additionally, Guident reported progress with their regenerative shock absorbers, with prototypes now fabricated and being evaluated by independent test facilities to confirm their performance and capabilities.
Tekcapital said Guident was in discussions with potential customers and strategic partners to both manufacture and use the regenerative shock absorbers.
"We have achieved what we believe to be one of the lowest glass-to-glass - or camera-to-monitor - latencies in the market," said Guident chairman and chief executive officer Harald Braun.
"This technology is required by teleoperations, which enables a human to remotely monitor and control an autonomous vehicle, as it facilitates rapid image analysis for quick decision making."
Seen this kind of FOOLish stuff on so many shares: IMO it's just their marketing technique.
They pick a share with an eye-catching recent rise that folks will have noticed and wished they had been holding, analyse it a bit with a mixed slant - they would look silly to say it was rubbish - and end by saying "Ah, but you haven't missed out, because we've got something better.... if you come into the Motley universe."
Just marketing. Can be useful to read for the summary but never listen to the message: it's there to make you buy their stuff.
This study is for MBC: metastatic breast cancer. But surely it makes it very likely that the system will work for most if not all metastatic cancers (and primaries?). I'm no medic but I would have thought that in time - the sooner the better - the first thing they do on suspicion of cancer is a pasortix blood test. Easy, cheap, fast, informative even with a negative result. What a result that would be for cancer treatment (as well the company).
… sleeping giant…..
This is back up near its peak, so for me I missed the opportunity to put back what I took out in January.
The news is very good, so it's not one to take profits from now, it's not a spike. NB The top 10 holders are all companies/ii's, and have ALL increased their holdings since March.
So for me I'm going to let it ride from here, maybe top up on any dip. If money available.
Signed, Lucksin. This has been the usual Boris disgrace.